Company Profile
SELLAS Life Sciences Group, Inc. Stock Price, News & Analysis
- Ticker:
- SLS
- Exchange:
- NASDAQ
- Sector:
- Life Science Tools
- Location:
- United States
Stock performance
11.70 USD (-1.35%)
Close
Last updated: August 6, 2026
1.55B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, SLS closed down 1.35% at $11.70. No new same-company headline was identified in the current news window.
Company overview
Business overview
SELLAS Life Sciences is a biopharmaceutical company focused on oncology, especially immunotherapies for cancer. Its story is built around a small set of development assets aimed at difficult tumors.
Geographic Base and Sector Classification
SELLAS is headquartered in the United States and listed on NASDAQ. It sits in small-cap oncology biotechnology.
Business Model Characteristics
The company depends on clinical data, translational confidence, and capital efficiency to keep its programs moving. Investors usually watch early readouts and strategic updates.
Position Within the Biotechnology Landscape
SELLAS occupies a small oncology niche within biotech. The stock tends to be driven by whether the company can produce a meaningful clinical signal.
Future catalysts
SELLAS’s catalysts are galinpepimut-S and its oncology-immunotherapy programs, plus any update that shows the company can keep the story alive. The stock is still data-sensitive.
Recent news
- 01
SELLAS Life Sciences to Participate in Upcoming Investor Conferences
Source: SELLAS Life Sciences Group, Inc.
- 02
SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
Source: SELLAS Life Sciences Group, Inc.
- 03
SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update
Source: SELLAS Life Sciences Group, Inc.
- 04
SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference
Source: SELLAS Life Sciences Group, Inc.
- 05
SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009
Source: SELLAS Life Sciences Group, Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of SELLAS Life Sciences Group, Inc. (SLS)?
SELLAS Life Sciences Group, Inc. (SLS) most recently closed at 11.70 USD, a -1.35% move versus the previous session.
What is the market cap of SELLAS Life Sciences Group, Inc. (SLS)?
SELLAS Life Sciences Group, Inc. currently has a market capitalization of 1.55B USD on BioPharmSignal.
What does SELLAS Life Sciences Group, Inc. do?
SELLAS Life Sciences is a biopharmaceutical company focused on oncology, especially immunotherapies for cancer. Its story is built around a small set of development assets aimed at difficult tumors.
On which exchange is SLS stock listed?
SELLAS Life Sciences Group, Inc. (SLS) is associated with NASDAQ, United States, Life Science Tools.
What is Life?
SELLAS Life Sciences is a biopharmaceutical company focused on oncology, especially immunotherapies for cancer.
Which conditions is SELLAS Life Sciences Group, Inc. targeting with Life?
SELLAS Life Sciences Group, Inc. is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does SELLAS Life Sciences Group, Inc. describe recent progress with Life?
SELLAS’s catalysts are galinpepimut-S and its oncology-immunotherapy programs, plus any update that shows the company can keep the story alive. The stock is still data-sensitive.
What is Sciences?
SELLAS Life Sciences is a biopharmaceutical company focused on oncology, especially immunotherapies for cancer.